G1T38, a novel, oral, potent and selective CDK4/6 inhibitor for the treatment of Rb competent tumors

被引：0
|
作者：
Sorrentino, Jessica A.
Bisi, John E.
Roberts, Patrick J.
Strum, Jay C.
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-2824
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2824
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors
    Bisi, John E.
    Sorrentino, Jessica A.
    Jordan, Jamie L.
    Darr, David D.
    Roberts, Patrick J.
    Tavares, Francis X.
    Strum, Jay C.
    ONCOTARGET, 2017, 8 (26) : 42343 - 42358
  • [2] FCN-437: A novel, potent and selective oral inhibitor of CDK4/6 for the treatment of solid tumors
    Lin, Shu
    Zhao, Xingdong
    Li, Tongshuang
    Zhang, Huajie
    Tan, Haohan
    Wang, Xianlong
    Jiang, Lihua
    Liu, Yanxin
    Sun, Jing
    Li Linghu
    Liu, Qihong
    Li, Zhifu
    Zhang, Weipeng
    Wang, Weibo
    CANCER RESEARCH, 2019, 79 (13)
  • [3] Characterization of a novel potent and selective CDK4/6 inhibitor and a resistance mechanism
    Dai, Kang
    Li, Cong
    Liang, Lingming
    Rong, Minging
    Orf, Jessica
    Keegan, Kathy
    Li, Zhihong
    Fu, Jiasheng
    Ma, Ji
    Carlson, Tim
    McGee, Larry
    Medina, Julio
    Kamb, Alexander
    Wickramasinghe, Dineli
    CANCER RESEARCH, 2012, 72
  • [4] The CDK4/6 inhibitor G1T38 enhances response to targeted therapies in preclinical models of non-small cell lung cancer
    Sorrentino, Jessica A.
    Freed, Daniel M.
    Bisi, John E.
    Strum, Jay C.
    Roberts, Patrick J.
    CANCER RESEARCH, 2018, 78 (13)
  • [5] G1T38, an oral CDK4/6 inhibitor, dosed continuously in combination with fulvestrant for HR plus breast cancer: Preliminary phase 1b results.
    Bulat, Iurie
    Maglakelidze, Marina
    Murias, Carmen
    Kurteva, Galina Petrova
    Roylance, Rebecca
    Gogiladze, Maia
    Crijanovschi, Adrian
    McCullough, Amy
    Shearin, Elizabeth
    Sorrentino, Jessica
    Sipes, Christina
    Yang, Zhao
    Cai, Yaping
    Malik, Rajesh K.
    Beelen, Andrew Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Effects of G1T48, a novel orally bioavailable selective estrogen receptor degrader (SERD), and the CDK4/6 inhibitor, G1T38, on tumor growth in animal models of endocrine resistant breast cancer
    Wardell, Suzanne E.
    Yllanes, Alexander P.
    Baker, Jennifer G.
    Baldi, Robert M.
    Krebs, Taylor K.
    Sorrentino, Jessica
    Bisi, John
    Strum, Jay
    Norris, John D.
    CANCER RESEARCH, 2017, 77
  • [7] Preclinical development of a highly potent and selective dual inhibitor of CDK4/6 for the treatment of cancer
    Bantie, Laychiluh
    Tadesse, Solomon
    Likisa, Jimma
    Yu, Mingfeng
    Noll, Benjamin
    Albrecht, Hugo
    Milne, Robert
    Wang, Shudong
    CANCER RESEARCH, 2018, 78 (13)
  • [8] Development and characterization of a novel CDK4/6 inhibitor for the treatment of CDK4/6 dependent cancers
    O'Brien, Neil A.
    McDermott, Martina S.
    O'Boyle, Brendan M.
    Hilf, Justin A.
    Loson, Oliver
    Chau, Kevin
    Jia, Weiping
    Kamranpour, Naeimeh
    Luo, Tong
    Ayala, Raul
    Issakhanian, Shawnt
    Glaspy, John A.
    Stoltz, Brian M.
    Slamon, Dennis J.
    CANCER RESEARCH, 2023, 83 (07)
  • [9] Lerociclib (G1T38), an oral CDK4/6 inhibitor, dosed continuously in combination with osimertinib for EGFRmut non-small cell lung cancer: Initial phase Ib results
    Berz, D.
    Spira, A.
    Gadgeel, S. M.
    Anderson, I. C.
    Goldman, J. W.
    Thompson, J.
    Foster, T.
    Pritchett, Y. L.
    Cisneros, C. G.
    Li, C.
    Sorrentino, J. A.
    Malik, R.
    Beelen, A. P.
    ANNALS OF ONCOLOGY, 2019, 30
  • [10] CDK4/6 inhibitor combination therapy for the treatment of RB1-intact HCC
    Sheng, Jindan
    Kohno, Susumu
    Takahashi, Chiaki
    CANCER SCIENCE, 2022, 113 : 555 - 555
12345